Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 EUR | +1.82% | +1.90% | -30.41% |
May. 31 | Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment | MT |
May. 31 | Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug | MT |
Sales 2024 * | 313M 339M | Sales 2025 * | 302M 328M | Capitalization | 1.7B 1.84B |
---|---|---|---|---|---|
Net income 2024 * | -13M -14.1M | Net income 2025 * | -71M -77M | EV / Sales 2024 * | -5.34 x |
Net cash position 2024 * | 3.37B 3.65B | Net cash position 2025 * | 2.97B 3.22B | EV / Sales 2025 * | -4.22 x |
P/E ratio 2024 * |
-43.7
x | P/E ratio 2025 * |
-16.4
x | Employees | 1,123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.64% |
Latest transcript on Galapagos NV
1 day | +1.82% | ||
1 week | +1.90% | ||
1 month | -3.16% | ||
3 months | -21.74% | ||
6 months | -24.54% | ||
Current year | -30.41% |
Managers | Title | Age | Since |
---|---|---|---|
Paulus Stoffels
CEO | Chief Executive Officer | 62 | 22-03-31 |
Thad Huston
DFI | Director of Finance/CFO | 54 | 23-05-31 |
Investor Relations Contact | - | 20-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Dickinson
BRD | Director/Board Member | 54 | Mar. 26 |
Jérôme Contamine
BRD | Director/Board Member | 66 | 22-04-25 |
Simon Sturge
BRD | Director/Board Member | 65 | 23-09-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.28% | 21 M€ | +1.54% | ||
0.03% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - | |
0.00% | 45 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 25.74 | +1.82% | 175,891 |
24-05-30 | 25.28 | +1.44% | 52,429 |
24-05-29 | 24.92 | -0.88% | 79,743 |
24-05-28 | 25.14 | -0.55% | 39,084 |
24-05-27 | 25.28 | +0.08% | 37,043 |
Real-time Euronext Amsterdam, May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.41% | 1.84B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- GLPG Stock